Ординатура / Офтальмология / Английские материалы / Essentials in Ophthalmology Medical Retina_Holz, Speide_2007
.pdf
Subject Index 215
N
N-retinylidene-N-retinyl- ethanolamine (A2E) 177
N-retinylidene-PE 176 N-retinylidene-phosphatid-
ylethanolamine 165, 175 negative scotoma 185 neovascular glaucoma 159 neovascular membranes 192 nephropathy 136 neuro-ophthalmological
disorders 2 neurosensory retina 27, 115 nictalopia 166
nitrous oxide synthase (NOS) 55
noninfectious endophthalmitis–
see pseudo-endophthalmitis nonproliferative diabetic
retinopathy 13 NOS–see nitrous oxide
synthase
O
OCT–see optical coherence tomography (OCT)
Octopus static perimetry 2 ocular adnexa 74, 81 ocular hypertension 67, 80
ocular neovascularization 91 omega-3 long-chain
polyunsaturated fatty acids 105, 107
opacity 29 ophthalmoscopy 29 opsin 177
optical coherence tomography (OCT) 8, 12, 13, 58, 131, 133, 134, 149, 185
–Stargardt’s disease 172 optic nerve fibers 204 optic nerve head 7
optic nerve sheath
–external
decompression 157
oral hypoglycemic agents 132
oxidative stress 105, 106, 132 oxygenated hemoglobin
(choroidal blood) 22
P
paclitaxel 92
panretinal photocoagulation (PRP) 138, 150
paracentesis 78, 85 paracentral scotomata 10 paragraph reading 205
pars plana vitrectomy 74, 77, 139, 156, 158
pattern electroretinogram (PERG) 166
pattern electroretinography (PERG) 27
PDT–see photodynamic therapy (PDT)
pegaptanib 53, 55, 59, 61, 69, 74, 78, 79, 94, 96, 140, 155
– ocular adverse events 70 pentoxifylline 150 PERG–see pattern
electroretinography pericytes 92
perifoveal telangiectasia 183 periocular steroid 140 periorbital swelling 76 phacoemulsification 141 phosphatidylethanolamine
(PE) 175, 176 phosphenes 199, 203 photodynamic therapy
(PDT) 10, 57, 89, 97, 98, 105, 193
photomontages of static images 30
photophobia 76, 85, 166 photoreceptor 106 photoreceptor cells 27 phototransduction
cascade 177 phthisis 77 physiologic hypoxia 94 PIER study 57
pigment epithelial-derived factor (PEDF) 91
pigment epitheliumneuroretina complex 191
pixel vision 205 platelet-derived growth
factor 89
platelet-derived growth factor receptor (PDGFR) 95
pneumatic shooter 204 poly(lactic-co-glycolic) acid
(PLGA) 56 polycythemia vera 192 polyimide 201
posterior vitreous detachment (PVD) 142
povidine-iodine solution 60 povidine-iodine sticks 60 povidone-iodine
–anti-VEGF therapy 81 preferred retinal locus
(PRL) 4, 5, 8 PRL–see preferred retinal
locus
pro-apoptotic proteins 177 PRONTO study 58 prostate cancer 192 protan axis 174 PROTECT 96
protein C 55 protein kinase C
–isoform 136 proteinuria 62 proteoglycans 96
pseudo-endophthalmitis 75
–pain 76 pseudohypopyon 16 pseudophakia 121 pseudoxanthoma
elasticum 192 PTK787 63 punctate keratitis 72
R
radial optic neurotomy (RON) 157, 158
ranibizumab 53, 56, 57, 58, 61, 69, 74, 78, 79, 94, 96, 97, 140
–ocular adverse events 70
–pharmacokinetics 59
216 |
Subject Index |
|
|
|
|
|
|
|
|
|
|
|
reactive oxygen species 136 |
|
RON–see radial optic |
|
|
static fundus perimetry 3, 12 |
|||||
|
reading speed 124, 126 |
|
|
neurotomy |
|
|
sterile endophthalmitis– |
||||
|
recombinant tissue |
|
RPE 44 |
|
|
|
see pseudo-endophthalmitis |
||||
|
|
plasminogen activator (rt- |
|
ruboxistaurin mesylate |
136 |
|
sterile lid speculum 60 |
||||
|
|
PA) 157, 158 |
|
|
RVO–see retinal vein |
|
|
steroid glaucoma |
186 |
||
|
regenerative therapies 206 |
|
occlusion (RVO) |
|
|
steroid injection |
153 |
||||
|
renal disease 137 |
|
|
|
|
|
|
STGD–see Stargardt’s disease |
|||
|
resorbed flecks |
167 |
|
|
|
|
|
|
(STGD) |
|
|
|
retinal-retinal |
|
|
|
|
|
|
|
STGD-FFM–see Stargardt’s |
||
|
186 |
|
|
S |
|
|
|
||||
|
|
anastomosis |
|
|
|
|
|
disease-fundus |
|||
|
|
|
|
|
|
|
|
||||
|
retinal artery occlusions 78 |
|
scanning laser ophthalmoscope |
flavimaculatus |
|||||||
|
retinal detachment 60, 78 |
|
|
(SLO) 2, 9, 21, 24 |
|
|
stimulus diameters 3 |
||||
|
retinal diseases |
2 |
|
|
scleral ring sectioning |
157 |
|
strabismus 4 |
|
||
|
retinal dystrophy 165 |
|
|
SCORE study 147, 148, 155 |
streptotocin 133 |
|
|||||
|
retinal ganglion cells |
|
|
– inclusion and exclusion |
stroke 192 |
|
|||||
|
|
(RGC) 201 |
|
|
|
criteria 155 |
|
|
sub-threshold laser |
||
|
retinal hypoxia |
|
|
|
scotoma 6, 13, 15, 120, 123, |
coagulation 139 |
|||||
|
– |
triggers 151 |
|
191 |
|
|
|
subconjunctival injection |
|||
|
– |
venous occlusion- |
|
|
– size 7 |
|
|
|
– pain 72 |
|
|
|
|
induced 148 |
|
|
scotomata |
|
|
|
subretinal approach 203 |
||
|
retinal injuries |
73 |
|
|
– paracentral 10 |
|
|
subretinal fibrosis 168 |
|||
|
retinal interneurons 203 |
159 |
|
scrambled egg formation 16 |
subretinal hemorrhage 23 |
||||||
|
retinal neovascularization |
|
septic shock |
96 |
|
|
sunlight exposure 119 |
||||
|
retinal oxygenation 159 |
|
|
sheathotomy |
156 |
|
|
synchysis scintillans 192 |
|||
|
retinal pigment epithelial |
|
|
single-cell stimulation |
201 |
|
systematic evolution of ligands |
||||
|
|
(RPE) 74 |
|
|
|
single nucleotide |
|
|
by exponential enrichment |
||
|
retinal pigment epithelial |
|
|
polymorphisms (SNPs) 40, |
(SELEX) 55 |
|
|||||
|
|
(RPE) cells |
94 |
|
41 |
|
|
|
systemic arterial |
|
|
|
retinal pigment epithelium |
|
singlet oxygen 95 |
|
|
hypertension |
191 |
||||
|
– |
(RPE) 8, 36, 165, 169 |
|
|
slit-lamp biomicroscopy 169, |
|
|
||||
|
fluorescence 24 |
|
171 |
|
|
|
|
|
|||
|
retinal sensitivity 125, 126 |
|
slit-lamp examination |
85 |
|
|
|
||||
|
|
|
T |
|
|||||||
|
retinal telangiectasis 183 |
|
|
SLO–see scanning laser |
|
||||||
|
retinal toxicity 74 |
|
|
ophthalmoscope |
|
|
TDMO study 140 |
||||
|
retinal vasculature 192 |
|
smoking 46, 105, 119, 121, 136 |
tetracaine 60 |
|
||||||
|
retinal vein occlusion |
|
|
Snellen visual acuity 58 |
tight blood glucose |
||||||
|
– |
(RVO) 78, 147, 147–160 |
|
sorbitol 136 |
|
|
|
control 135 |
|
||
|
management strategies |
148 |
|
spastic paraplegia 192 |
|
|
tissue hydrostatic pressure 92 |
||||
|
– |
risk factors |
158 |
|
|
Staphylococcus aureus |
77 |
|
tissue oxygen tension 53 |
||
|
– |
systemic factors 158 |
199 |
|
staphyloma 23 |
|
|
toxic endophthalmitis– |
|||
|
retinitis pigmentosa (RP) |
|
Stargardt-like macular |
|
|
see pseudo-endophthalmitis |
|||||
|
rhodopsin 172, 175 |
|
|
dystrophy |
178 |
|
|
trabeculectomy 140 |
|||
|
RISC 62 |
|
|
Stargardt’s disease (STGD) 1, |
transpupillary thermotherapy |
||||||
|
RNA |
|
|
|
4, 15, 116, 118, 165–178 |
(TTT) 194 |
|
||||
|
– |
gene-specific double- |
|
|
Stargardt’s macular |
|
|
traumatic cataract 72 |
|||
|
– |
stranded 62 |
|
|
dystrophy |
37, 38 |
|
|
triamcinolone 56, 67, 68, 73, |
||
|
interference |
62 |
|
|
Stargardt’s macular dystrophy- |
74, 75, 77, 79, 84, 89, 95, |
|||||
|
RNAs (siRNAs) |
|
|
fundus flavimaculatus |
97, 98 |
|
|||||
|
– |
small interfering 62 |
|
|
(STGD-FFM) 27, 165 |
triamcinolone acetonide 151 |
|||||
|
|
|
|
|
|
Subject Index |
217 |
|
tritan axis 174 |
vascular endothelial growth |
vitreous floaters 74 |
|
|||||
tuberculin syringe 60 |
factor-A (VEGF-A) |
90 |
vitreous hemorrhage 74, 79, |
|
||||
tumor necrosis factor alpha |
Vascular leakage 55 |
93 |
149 |
|
|
|||
|
(TNFα) 89, 96, 98 |
vascular normalization |
vitreous reflux 72, 78 |
|
||||
tumor vascular permeability |
vasculogenesis 61 |
|
VMD2 gene 16 |
|
||||
|
factor (VPF) 53 |
vasoplegia |
96 |
|
VPF–see tumor vascular |
|
||
|
|
VEGF–see vascular |
|
permeability factor |
|
|||
|
|
endothelial growth factor |
|
|
|
|||
|
|
VEGF Inhibition Study in |
|
|
|
|||
|
U |
|
|
|
||||
|
Ocular Neovascularization |
W |
|
|
||||
UK Prospective Diabetes Study |
(VISION) 55 |
|
|
|
||||
|
|
|
|
|||||
|
(UKPDS) 135 |
venous thrombosis 156 |
|
warfarin sodium 150 |
|
|||
untreatable blindness 35 |
VERITAS study 56 |
|
wide-field camera systems 30 |
|
||||
uveitis 57, 63, 75 |
verteporfin 55, 57 |
|
wide-field contact lens |
|
||||
|
|
verteporfin PDT 58 |
|
system 29 |
|
|||
|
|
viral retinitis |
67 |
|
wide-field fluorescein |
|
||
|
|
VISION study 61 |
|
angiogram 30, 31 |
|
|||
|
V |
|
|
|||||
|
VISION trial |
69, 72, 74, 78, 79 |
|
|
|
|||
|
|
|
|
|
||||
vancomycin 78 |
visual acuity |
57, 62, 113, 124, |
|
|
|
|||
vascular disease 137 |
135, 157, 165, 168 |
|
|
|
|
|||
|
X |
|
|
|||||
vascular endothelial growth |
visual acuity loss 166 |
|
|
|
||||
|
factor (VEGF) 53, 89, 151, |
visual acuity measurement 123 |
xanthophylls 107 |
|
||||
|
193 |
visual function questionnaire |
|
|
|
|||
vascular endothelial growth |
(VFQ) |
133 |
|
|
|
|
||
|
factor (VEGF-A) 54 |
visual loss |
77 |
|
|
|
|
|
|
|
Z |
|
|
||||
vascular endothelial growth |
visual prostheses 206 |
|
|
|
||||
|
factor (VGEF) |
vitamin E |
107 |
|
zeaxanthin 105, 106, 188 |
|
||
– |
receptor tyrosine kinase |
vitelliform macular |
|
zinc 106, 108 |
|
|||
|
activity 63 |
dystrophy |
16 |
|
|
|
|
|
– |
VEGF trap 62 |
vitrectomy |
9, 75, 142, 156 |
|
|
|
||